[ad_1]
Enter 2020.10.15 06:00 | Revision 2020.10.15 10:00
Companies conducting Corona 19-related clinical trials are publicly reporting each company’s clinical progress through press releases. An official from a national pharmaceutical company said: “Unlike the fact that clinical trial information is rarely exposed to the outside, companies are vigorously promoting Corona 19-related clinical trials.”
Recently, the Ministry of Food and Pharmaceutical Safety decided to respond by unifying the process of clinical trials of COVID-19 treatments and vaccines by company. This is a measure that is mindful of the stock market fluctuation in ‘a word’ as there is great interest in COVID-19 treatments and vaccines around the world.
However, companies are still actively promoting the COVID-19 treatment and vaccine development process. After the government announcement, it is a way of remembering the contents related to a time lag. Initially, considering the confusion in the stock market, the companies also formed a consensus with the government to ‘regulate’ clinical trials, but only a few are noted.
On the 8th of this month, the Ministry of Food and Pharmaceutical Safety Daewoong Pharmaceutical (069620)He announced that he has approved a phase 1 clinical trial for the COVID-19 treatment ‘DWRX2003’ in development. Soon after, on the 12th, Daewoong Pharmaceutical published a press release stating that it had been approved for a phase 1 clinical trial of ‘DWRX2003’ from the Ministry of Food and Drug Safety.
When Celltrion announced on September 17 that the Ministry of Food and Drug Safety had approved the phase 2 and 3 clinical trial plan for COVID-19 antibody treatment ‘CT-P59’, it published data based on similar content. .
Not only domestic but also foreign companies are actively promoting the contents of clinical trials related to COVID-19. Regeneron, who is developing an antibody treatment known to have been administered to the President of the United States, Donald Trump, has released a press release stating that the preliminary results of the clinical trial are good, but did not reveal any data. specific to the test.
Experts are skeptical about the disclosure of clinical progress, as there is uncertainty before the conclusion of phase 3 clinical trials. This is because companies that have been actively involved in the development of COVID-19 treatments and vaccines at home and abroad have announced the suspension of phase 3 clinical trials.
National company on this day Komi Farm (041960)He announced that he had been rejected by the Spanish health authorities for a phase 2 and 3 test plan for the treatment of COVID-19. The company has been promoting clinical trials in which ‘PAX01’, which had been developed as a pain medication using arsenic compounds, was administered to patients with severe pneumonia caused by Corona 19. The reason for the rejection of the plan clinical trial was lack of documentation. The Spanish authorities requested that Komifam be submitted as a supplement and supplementary data, but the clinical trial plan was rejected that day.
On the 13th, the 13th, a day after Johnson & Johnson in the United States announced that it would suspend the phase 3 clinical trial of a COVID-19 vaccine candidate due to the side effects of the participants, Eli Lilly suspended the clinical trial delayed COVID-19 antibody treatment due to safety concerns. I did it with the key. Eli Lilly’s antibody therapy is the same type of drug Regeneron is developing. Previously, AstraZeneca, UK, also stopped and resumed the trial due to some side effects in the final stage of the Corona 19 vaccine clinical trial that was being developed.
Kim Woo-joo, professor of infectious medicine at Korea University Guro Hospital, said, “Even during clinical trials (companies that develop COVID-19 treatments and vaccines), press releases are popping up.” He said. He added: “In Korea, company executives are reporting this directly,” he added. “As the situation is now, it seems to be seeing some effects.”
